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Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system. Natalizumab, a humanized
anti-𝛼4 integrinmonoclonal antibody, is a highly effective treatment approved forMS. An association betweenMS and an exposure
to Epstein-Barr Virus (EBV) sustained by the levels of antiviral capsid antigen (VCA) and anti-Epstein-Barr nuclear antigen-1
(EBNA-1) IgG has been described. Our goal was to verify the utility of EBV-specific IgG as a marker in Natalizumab treated MS.
Twenty patients (17 female and 3 male) in treatment with Natalizumab were enrolled. Serum levels of anti-VCA and anti-EBNA-1
IgG were determined and expressed as arbitrary units (AU) before treatment and every three months for 21 months of therapy.
Anti-VCA IgG levels were increased at the 15th month (235410 ± 196712AU) comparing with the 3rd (98146 ± 47145AU) and the
6th (109866 ± 52270AU) months of therapy (𝑝 < 0.05). No significant differences were found for serum anti-EBNA-1 IgG levels.
Our data indicate that a transient, self-limited, EBV reactivation can occur in MS during Natalizumab therapy but our results do
not support the use of serum EBV-specific antibody levels as biomarkers for monitoring therapeutic response to Natalizumab in
the course of MS.
1. Introduction
Multiple sclerosis (MS) is considered an autoimmune chronic
inflammatory disease of the central nervous system (CNS) of
unclear etiology that is marked by demyelination and axonal
loss [1]. MS usually occurs in young adults, is more frequent
in women than in men, and is characterized by clinical
attacks or exacerbations, called relapses, which typically show
a dissemination in space and time [2]. Lymphocytemigration
across the blood-brain barrier (BBB) is thought to be a crucial
step in the initiation and maintenance of brain inflammatory
reaction [3]. The interaction of 𝛼4𝛽1 integrin, a protein
on the surface of lymphocytes, with vascular-cell adhesion
molecule-1 (VCAM-1), which is expressed on the surface
of vascular endothelial cells in brain and spinal cord blood
vessels, mediates the adhesion and migration of lymphocytes
in areas of CNS inflammation [4]. Natalizumab (Tysabri,
Biogen Idec Inc., Cambridge, Massachusetts, USA), a hu-
manized anti-𝛼4 integrin monoclonal antibody, is a highly
effective treatment approved for relapsing remitting multiple
sclerosis (RRMS) [5, 6]. Natalizumab is administered in-
travenously to RRMS patients once every 4 weeks in a dose
of 300mg, and its efficacy in substantially reducing relapse
rate and the progression of disability has been shown in
clinical trials [7]. Therefore, Natalizumab is currently used as
second-line treatment in MS patients who have a suboptimal
response to first-line disease-modifying therapies or as first-
line therapy in those with highly active disease [8]. However,
despite the undisputable benefits, anti-𝛼4 integrin treatment
is associated with John CunninghamVirus- (JCV-) mediated
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progressive multifocal leukoencephalopathy (PML), an un-
favourable and severe adverse event [9]. Although disease
etiology remains largely unknown, epidemiological studies
suggest that the combination of exposure to an environ-
mental factor, such as an infectious agent, and genetic
predisposition could play a crucial role in MS pathogenesis
[10]. In this setting, an ideal candidate is represented by
Epstein-Barr Virus (EBV), a human 𝛾-herpesvirus which can
infect, activate, and latently persist in B-lymphocytes for life
[11]. In a meta-analysis of previously published case-control
observational studies [12], the authors found an association
between MS and exposure to EBV which was particularly
sustained by the levels of antiviral capsid antigen (VCA) IgG
and anti-Epstein-Barr nuclear antigen-1 (EBNA-1) IgG. No
significant association was found when studying anti-early
antigen (EA) IgG. In addition, it has been demonstrated that
a past infectious mononucleosis (IM) was frequent and the
seroprevalence of anti-EBNA-1 and anti-VCA IgG was higher
in MS patients than in controls [13, 14]. Elevated serum levels
of anti-EBNA-1 IgG were associated with an increased risk of
developing MS [15] and disease activity [16] and were found
to be predicting factors for the conversion from clinical iso-
lated syndrome (CIS) to definite MS [17]. On the other hand,
high serum concentrations of anti-VCA IgG were related to
grey matter atrophy [18]. Taken together, these observations
suggest that EBV-specific antibody response could be used as
amarker for disease development and activity.This possibility
was further corroborated by the repeated evidence that anti-
EBNA-1 serum titers were greater in MS than in controls [19,
20]. Nevertheless, whether serum concentrations of anti-EBV
antibodies can actually serve as biomarker for monitoring
MS treatment response is still to be established. For this
reason, the potential of serum concentrations of anti-EBNA-
1 as indicators of MS disease activity was recently tested in a
small population of treatment-na¨ıve MS patients before and
after 12 months of therapy with Natalizumab, with negative
results [21]. Therefore, the aim of our study was to verify the
effective utility of EBV-specific serum antibodies as a marker
for the response to treatment with Natalizumab in a cohort of
relapsing remittingmultiple sclerosis (RRMS) patients during
21 months of therapy.
2. Materials and Methods
2.1. Study Design and Sample Handling. This study included
20 consecutive patients (17 female and 3 male) with definite
RRMS [22] in treatment with Natalizumab after discon-
tinuation of therapy with immunomodulatory or immuno-
suppressive drugs (6 on glatiramer acetate, 5 on interferon
𝛽-1a, 4 on interferon 𝛽-1b, 4 on mitoxantrone, and 1 on
cyclophosphamide) due to unresponsiveness represented by
the occurrence of at least one relapse in the previous year.
Patients were enrolled at the “Fondazione Istituto Neuro-
logico C. Mondino” in Pavia. Serum samples were collected
at baseline and consecutively at 3, 6, 9, 12, 15, 18, and 21
months after the initiation of Natalizumab therapy. At all
time points, (a) disease severity was scored using Kurtzke’s
Expanded Disability Status Scale (EDSS) [23]; (b) presence of
relapse, defined as the onset of new or recurrent symptoms
or signs or the worsening of already present neurological
abnormalities persisting for at least 24 h in the absence of
fever and preceded by at least 1 month of stable or improved
neurological state, was recorded as clinical activity; and (c)
anti-JCV serostatus was determined to prevent the risk of
PML in accordance with previous validated enzyme-linked
immunosorbent assay (ELISA) protocol [24]. Disability pro-
gression during Natalizumab treatment was defined as an
increase of one point on EDSS score from baseline [5].
All patients underwent brain Magnetic Resonance Imaging
(MRI) scans at entry and at the end of the study and the
occurrence of a new lesion on T2-weighted scans and/or
a new gadolinium- (Gd-) enhancing lesion on T1-weighted
scans was defined as MRI activity [22]. None of the patients
had been receiving corticosteroids at the time of sample
collection.The approval of the Committee for Medical Ethics
in Research as well as written informed consent from all sub-
jects participating in the study was obtained for experiments
involving human subjects.
2.2. Serum Levels of Anti-Epstein-Barr Virus Antibodies.
Serum concentrations of anti-EBNA-1 and anti-VCA IgG
were measured by ELISA using commercially available
ELISA kits (Novagnost EBV-EBNA1 IgG and EBV-VCA
IgG, codes numbers EBVG0580DB and EBVG0150DB, resp.)
as described elsewhere [19, 20]. All reagents, plates, and
peroxidase-conjugated antibody were included in the kits.
Microtiter strip wells were precoated with recombinant
EBNA-1 and synthetic VCA (p18) antigens, respectively.
A reference curve was generated in each assay using six
serial dilutions of pooled EBV-high-positive serum samples
ranging between 0.1 and 2.0OD. Serum samples, prediluted
1 : 100 or 1 : 1200, were dispensed in duplicate into two
microtiter plates, one precoated with EBNA-1 and the other
precoated with VCA. A reference curve was generated in
each assay using the pooled serum samples by plotting the
concentrations, expressed as arbitrary units (AU), versus the
relative optical density (OD) values. For each sample, anti-
EBNA-1 and anti-VCA IgG concentrations were obtained by
multiplying AU value for the corresponding dilution factor.
2.3. Data Analysis. Statistical analysis was performed with
GraphPad Prism. After checking data for normality bymeans
of the Kolmogorov-Smirnov test, a normality of data distri-
bution was rejected in several variables. Therefore, statistical
analysis was performed through a nonparametric approach.
More precisely, continuous variables were compared using
Kruskal-Wallis test and Friedman test for repeated measures.
Dunn’s test correction was utilized for multiple comparisons.
A value of 𝑝 < 0.05 was accepted as statistically significant.
3. Results
Demographic and clinical characteristics of 20 RRMS
patients receiving Natalizumab are listed in Table 1. During
Natalizumab treatment, (a) five patients had relapses (3
patients had 1 relapse between baseline and 3months, one had
2 relapses between 6 and 9months and at 12 months, and one
had 2 relapses between 9 and 12months and between 18 and 21
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Figure 1: Longitudinal fluctuations of anti-EBNA-1 and anti-VCA IgG in the ten patients with relapsing remitting multiple sclerosis (RRMS)
treated with Natalizumab for 21 months in which blood samples were taken at every time point. Serum levels of anti-EBNA-1 and anti-VCA
IgGwere different among various time points (Friedman test: 𝑝 < 0.05 and 𝑝 < 0.01, resp.). Serum levels of anti-VCA IgGwere more elevated
at 𝑇15 compared to 𝑇3 and 𝑇6 (Dunn’s posttest: 𝑝 < 0.05) whereas no differences were found comparing each time point for EBNA-1 IgG
levels in a post hoc analysis. AU = arbitrary units; EBNA-1 = Epstein-Barr nuclear antigen-1; 𝑇0 = baseline; 𝑇3 = the 3rd month; 𝑇6 = the 6th
month; 𝑇9 = the 9th month; 𝑇12 = the 12th month; 𝑇15 = the 15th month; 𝑇18 = the 18th month; 𝑇21 = the 21st month; VCA = viral capsid
antigen. Horizontal bars indicate medians and error bars correspond to interquartile range.
Table 1: Demographic, clinical, and radiological characteristics in
20 relapsing remitting multiple sclerosis (RRMS) patients receiving
Natalizumab.
Sex: female/male 17/3
Age at entry, years: mean ± SD 34.2 ± 9.8
Disease duration at baseline, years (mean ± SD) 10.2 ± 6.2
Disease severity at baseline, EDSS: mean ± SD 1.3 ± 1.5
EDSS after 21 months of treatment (mean ± SD) 1.7 ± 1.7
Relapsing/nonrelapsing patients during 21 months
of therapy 5/15
Patients with/without new MRI lesions at the end
of treatment 4/20
EDSS = Expanded Disability Status Scale; MRI = Magnetic Resonance
Imaging; SD = standard deviation.
months); (b) no patients had a progression of disability from
baseline; and (c) four patients showed a new 𝑇2 and/or Gd-
enhancing lesions on the last MRI examination at 21 months,
but none of these had relapses. No patients showed anti-JCV
seropositive during the 21 months of Natalizumab therapy.
Only for ten patients, it was possible to perform a longitudinal
determination of EBV-specific antibodies at each time point
(of these, 2 patients had 1 relapse between baseline and 3
months and one had 2 relapses between 9 and 12 months and
between 18 and 21 months), whereas for the remaining ten
patients the timing of sample collection was not sequential
and so resulted incomplete. Serum levels of anti-EBNA-1 and
anti-VCA IgG were detected in all samples. As reported in
Table 2, when MS patients were analyzed as a whole, no
significant differences were found for serum concentrations
of either anti-EBNA-1 or anti-VCA IgG levels among the
various time points. Conversely, when we evaluated only MS
patients in whom serum samples were available at all time
points (Figure 1), serum levels of anti-EBNA-1 and anti-VCA
IgG were statistically different among the various time points
(Friedman test: 𝑝 < 0.05 and 𝑝 < 0.01, resp.). However, post
hoc analysis revealed that while anti-VCA IgG levels were
significantly higher at the 15th month than at the 3rd and the
6th months after the beginning of therapy (Dunn’s posttest:
𝑝 < 0.05), no significant differences were found for serum
anti-EBNA-1 IgG levels among the different time points.
4. Discussion
This study has demonstrated for the first time that temporal
fluctuations of serum levels of EBV-specific IgG in RRMS
could be affected by treatment with Natalizumab. In recent
decades, several studies have shown that an association
can exist between antibodies specific for EBV antigens, in
particular EBNA-1 and VCA, and some clinical features of
MS, such as disease initiation and activity [11–18].Thus, these
antibodies are considered as putative biomarkers which may
be useful for describing the natural history of the disease
or “type 0 biomarkers” following the definition of Bielekova
and Martin [25]. The purpose of our study was to investigate
whether EBV-specific antibodies could also be used in RRMS
patients as “type I biomarkers” to capture the effects of
Natalizumab intervention in accordance with its mechanism
of action [25]. In agreement with other investigators [21],
our results confirmed that anti-EBV antibodies are not a
useful marker of disease activity in patients treated with
Natalizumab. In fact, anti-VCA IgG serum levels peaked at
the 15th month after the start of therapy when no patients
had clinical activity, as indicated by lack of the occurrence
of a relapse. In addition, MRI activity was present in only
four patients on the last examination at the 21st month
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Table 2: Longitudinal fluctuations in serum anti-EBNA-1 and anti-VCA IgG levels in relapsing remitting multiple sclerosis (RRMS) patients,
considered as a whole, during 21 months of Natalizumab treatment.
Time point (sample)
Serum anti-EBNA-1 IgG levels
(AU)
median, IQR
Serum anti-VCA IgG levels
(AU)
median, IQR
𝑇0 (𝑛 = 16) 273750, 160073–411955 107720, 44682–151729
𝑇3 (𝑛 = 19) 264992, 133546–372122 82629, 45782–134306
𝑇6 (𝑛 = 19) 299852, 149020–415994 103548, 52914–158579
𝑇9 (𝑛 = 19) 272304, 151911–433509 100277, 73889–172901
𝑇12 (𝑛 = 20) 234446, 159224–369656 112400, 59598–195399
𝑇15 (𝑛 = 18) 218906, 164613–356031 110428, 88676–276036
𝑇18 (𝑛 = 19) 230182, 136390–410000 145650, 98579–310823
𝑇21 (𝑛 = 18) 239703, 163733–366165 115988, 77566–379377
AU = arbitrary units; EBNA-1 = Epstein-Barr nuclear antigen-1; IQR = interquartile range; SD = standard deviation; 𝑇0 = baseline; 𝑇3 = the 3rd month; 𝑇6
= the 6th month; 𝑇9 = the 9th month; 𝑇12 = the 12th month; 𝑇15 = the 15th month; 𝑇18 = the 18th month; 𝑇21 = the 21st month; VCA = Epstein-Barr viral
capsid antigen.
when serum concentrations of EBV-specific antibodies did
not differ compared to baseline and the other time points.
However, here we documented that serum levels of anti-VCA
IgG were transiently increased during Natalizumab therapy
since they were more elevated at the 15th month than at
the 3rd and the 6th months of treatment. This finding is
difficult to interpret in the absence of clinical evidence of
disease activity.The presence of a dysregulated EBV infection
of the CNS has recently been suggested [26]. Therefore,
we are tempted to speculate that Natalizumab treatment,
interfering with the EBV-specific CD8+ trafficking into CNS,
could promote an EBV reactivation within the brain with a
consequent release of antigens from theCNS to the periphery.
Thus, the presence of these antigens may induce a peripheral
production of EBV-specific antibodies. Nevertheless, the
lacking of a simultaneous JCV reactivation, as shown by JCV-
specific seronegativity at the same time point, weakens the
consistency of this hypothesis [21]. Alternatively, this tran-
sient elevation of anti-VCA IgG may represent a reactivation
of EBV infection in systemic compartment due to a prolonged
immunosuppression in peripheral organs induced by Natal-
izumab [27]. However, this possibility is not sustained by the
demonstration that the amounts of blood activated CD8+ T-
cells releasing proinflammatory cytokines were enhanced in
MS patients treated with Natalizumab [28]. Moreover, this
speculation could be confirmed by the concomitant increased
of anti-early antigen (EA) antibodies which, however, have
not been measured in this study due to the conflicting
results previously obtained on their ability in identifying
EBV reactivation [12]. On the other hand, it is interesting to
note that only anti-VCA IgG and not anti-EBNA-1 IgG was
increased. As VCA are viral surface proteins and EBNA-1
represent nuclear viral proteins, this result could be explained
by the different biological significance of these two different
antibodies. In fact, it has been postulated that EBV acts as an
intermittently cytopathic virus [29] that latently persists life-
long in B-cells and causes recurring reactivations [30]. Lytic
proteins, including VCA, are expressed during replication
whereas latent genes, including EBNAs, are expressed in the
growth phases of infection [11]. In this way, the transient
increase in the serum anti-VCA IgG levels we observed at
the 15th month may reflect an ongoing and self-limiting
replicative EBV infection [29, 30]. The main limitations of
this study were certainly the small sample size and the
presence of some patients in whom not all serum samples
were available. Another limiting factor is the lack of samples
collected at the time of relapse which could contribute to a
more reliable identification of possible correlations between
EBV-specific antibodies and disease activity. Taken together,
although these data indicate that a transient self-limited EBV
reactivation can occur in RRMS duringNatalizumab therapy,
they argue against the use of serum EBV-specific antibody
levels as biomarkers for monitoring therapeutic response to
Natalizumab in the course of RRMS. However, future studies
are needed to verify the actual significance of anti-EBV
antibodies in MS patients who are undergoing Natalizumab
therapy.
Conflict of Interests
The authors declare that they have no conflict of interests.
Acknowledgments
This work has been supported by Research Program
Regione Emilia Romagna-University 2007–2009 (Innovative
Research), entitled “Regional Network for Implementing a
Biological Bank to Identify Biological Markers of Disease
Activity Related to Clinical Variables in Multiple Sclerosis.”
The authors thank Dr. Serena Ruggieri for her technical
contribution andDr. Elizabeth Jenkins for helpful corrections
of the paper.
References
[1] J. Goverman, “Autoimmune T cell responses in the central
nervous system,” Nature Reviews Immunology, vol. 9, no. 6, pp.
393–407, 2009.
[2] A. Compston and A. Coles, “Multiple sclerosis,”The Lancet, vol.
359, no. 9313, pp. 1221–1231, 2002.
Disease Markers 5
[3] M. Sospedra andR.Martin, “Immunology ofmultiple sclerosis,”
Annual Review of Immunology, vol. 23, pp. 683–747, 2005.
[4] J. J. Campbell, J. Hedrick, A. Zlotnik, M. A. Siani, D. A.
Thompson, and E. C. Butcher, “Chemokines and the arrest of
lymphocytes rolling under flow conditions,” Science, vol. 279,
no. 5349, pp. 381–384, 1998.
[5] C. H. Polman, P. W. O’Connor, E. Havrdova et al., “A ran-
domized, placebo-controlled trial of natalizumab for relapsing
multiple sclerosis,” The New England Journal of Medicine, vol.
354, no. 9, pp. 899–910, 2006.
[6] E. Havrdova, S. Galetta, M. Hutchinson et al., “Effect of natal-
izumab on clinical and radiological disease activity in multiple
sclerosis: a retrospective analysis of the Natalizumab Safety and
Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM)
Study,”The Lancet Neurology, vol. 8, no. 3, pp. 254–260, 2009.
[7] J. Chataway andD.H.Miller, “Natalizumab therapy formultiple
sclerosis,” Neurotherapeutics, vol. 10, no. 1, pp. 19–28, 2013.
[8] L. Kappos, D. Bates, G. Edan et al., “Natalizumab treatment
for multiple sclerosis: updated recommendations for patient
selection and monitoring,”The Lancet Neurology, vol. 10, no. 8,
pp. 745–758, 2011.
[9] G. Bloomgren, S. Richman, C. Hotermans et al., “Risk of
natalizumab-associated progressive multifocal leukoencepha-
lopathy,”The New England Journal of Medicine, vol. 366, no. 20,
pp. 1870–1880, 2012.
[10] E. Fainardi, M. Castellazzi, S. Seraceni, E. Granieri, and C.
Contini, “Under the microscope: focus on Chlamydia pneumo-
niae infection and multiple sclerosis,” Current Neurovascular
Research, vol. 5, no. 1, pp. 60–70, 2008.
[11] R. M. Lucas, A. M. Hughes, M.-L. J. Lay et al., “Epstein-Barr
virus andmultiple sclerosis,” Journal of Neurology, Neurosurgery
and Psychiatry, vol. 82, no. 10, pp. 1142–1148, 2011.
[12] O. Santiago, J. Gutierrez, A. Sorlozano, J. de Dios Luna, E. Vil-
legas, and O. Fernandez, “Relation between Epstein-Barr virus
and multiple sclerosis: analytic study of scientific production,”
European Journal of Clinical Microbiology & Infectious Diseases,
vol. 29, no. 7, pp. 857–866, 2010.
[13] A. E. Handel, A. J. Williamson, G. Disanto, L. Handunnetthi, G.
Giovannoni, and S.V. Ramagopalan, “Anupdatedmeta-analysis
of risk of multiple sclerosis following infectious mononucleo-
sis,” PLoS ONE, vol. 5, no. 9, Article ID e12496, 2010.
[14] Y. H. Almohmeed, A. Avenell, L. Aucott, and M. A.
Vickers, “Systematic review and meta-analysis of the sero-
epidemiological association between Epstein-Barr virus and
multiple sclerosis,” PLoS ONE, vol. 8, no. 4, Article ID e61110,
2013.
[15] A. Ascherio and K. L.Munger, “Epstein-Barr virus andmultiple
sclerosis: a review,” Journal of Neuroimmune Pharmacology, vol.
5, no. 3, pp. 271–277, 2010.
[16] R. A. Farrell, D. Antony, G. R. Wall et al., “Humoral immune
response to EBV in multiple sclerosis is associated with disease
activity on MRI,” Neurology, vol. 73, no. 1, pp. 32–38, 2009.
[17] J. D. Lu¨nemann, M. Tintore´, B. Messmer et al., “Elevated
Epstein-Barr virus-encoded nuclear antigen-1 immune re-
sponses predict conversion tomultiple sclerosis,”Annals of Neu-
rology, vol. 67, no. 2, pp. 159–169, 2010.
[18] R. Zivadinov, M. Zorzon, B. Weinstock-Guttman et al.,
“Epstein-Barr virus is associated with grey matter atrophy
in multiple sclerosis,” Journal of Neurology, Neurosurgery and
Psychiatry, vol. 80, no. 6, pp. 620–625, 2009.
[19] M. Castellazzi, C. Tamborino, A. Cani et al., “Epstein-Barr
virus-specific antibody response in cerebrospinal fluid and
serumof patients withmultiple sclerosis,”Multiple Sclerosis, vol.
16, no. 7, pp. 883–887, 2010.
[20] M. Castellazzi, C. Contini, C. Tamborino et al., “Epstein-
Barr virus-specific intrathecal oligoclonal IgG production in
relapsing-remitting multiple sclerosis is limited to a subset of
patients and is composed of low-affinity antibodies,” Journal of
Neuroinflammation, vol. 11, no. 1, article 188, 2014.
[21] J. Raffel, R. Dobson, A. Gafson,M.Mattoscio, P.Muraro, and G.
Giovannoni, “Multiple sclerosis therapy and Epstein-Barr virus
antibody titres,”Multiple Sclerosis and Related Disorders, vol. 3,
no. 3, pp. 372–374, 2014.
[22] C. H. Polman, S. C. Reingold, B. Banwell et al., “Diagnostic
criteria for multiple sclerosis: 2010 revisions to the McDonald
criteria,” Annals of Neurology, vol. 69, no. 2, pp. 292–302, 2011.
[23] J. F. Kurtzke, “Rating neurologic impairment in multiple sclero-
sis: an expanded disability status scale (EDSS),” Neurology, vol.
33, no. 11, pp. 1444–1452, 1983.
[24] L. Gorelik, M. Lerner, S. Bixler et al., “Anti-JC virus antibodies:
implications for PML risk stratification,” Annals of Neurology,
vol. 68, no. 3, pp. 295–303, 2010.
[25] B. Bielekova and R. Martin, “Development of biomarkers in
multiple sclerosis,” Brain, vol. 127, no. 7, pp. 1463–1478, 2004.
[26] B. Serafini, B. Rosicarelli, D. Franciotta et al., “Dysregulated
Epstein-Barr virus infection in the multiple sclerosis brain,”
Journal of Experimental Medicine, vol. 204, no. 12, pp. 2899–
2912, 2007.
[27] O. Stu¨ve, R. Gold, A. Chan, E. Mix, U. Zettl, and B. C. Kieseier,
“Alpha4-integrin antagonism with natalizumab: effects and
adverse effects,” Journal of Neurology, vol. 255, supplement 6,
pp. 58–65, 2008.
[28] P. Kivisa¨kk, B. C. Healy, V. Viglietta et al., “Natalizumab treat-
ment is associated with peripheral sequestration of proinflam-
matory T cells,” Neurology, vol. 72, no. 22, pp. 1922–1930, 2009.
[29] L.Hangartner, R.M. Zinkernagel, andH.Hengartner, “Antiviral
antibody responses: the two extremes of a wide spectrum,”
Nature Reviews Immunology, vol. 6, no. 3, pp. 231–243, 2006.
[30] M. P. Pender, “The essential role of Epstein-Barr virus in the
pathogenesis of multiple sclerosis,” Neuroscientist, vol. 17, no. 4,
pp. 351–367, 2011.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
